Evidence map›Paper›PMID 36685668›Full record

ArticleBioMed research international2023

Characterisation of APS-1 Experimental Models Is Crucial for Development of Novel Therapies.

Sarah Almaghrabi, Thomas Lovewell, Mimoun Azzouz, Rachid Tazi Ahnini

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sarah AlmaghrabiDepartment of Infection, Immunity and Cardiovascular Disease, Sheffield, UK.
Thomas LovewellDepartment of Infection, Immunity and Cardiovascular Disease, Sheffield, UK.
Mimoun AzzouzSheffield Institute for Translational Neuroscience (SITRaN), Department of Neuroscience, The Medical School, University of Sheffield, Sheffield S10 2RX, UK.
Rachid Tazi AhniniDepartment of Infection, Immunity and Cardiovascular Disease, Sheffield, UK.ORCID https://orcid.org/0000-0002-1268-7845
University of Sheffield · GB

Funding

Medical Research Council MR/V030140/1
6 · The paper itself

Abstract

Autoimmune polyglandular syndrome type 1 (APS-1) is an inherited autosomal disorder. The most common clinical features of the disease include adrenocortical failure, hypoparathyroidism (HP), and chronic mucocutaneous candidiasis (CMC). APS-1 is caused by mutations in the autoimmune regulator (AIRE) gene. AIRE is a transcriptional factor involved in the regulation of thousands of genes in the thymus. It facilitates central tolerance by promoting the ectopic expression of tissue-specific antigens (TSAs) in medullary thymic epithelial cells (mTECs), leading to the deletion of self-reactive thymocytes. Several Aire-deficient mice were developed separately, on different backgrounds; seven published Aire knockout mice show a variety of phenotypes depending on the strain used to generate the experimental model. The first Aire-deficient mice were generated on a "black 6" background almost 20 years ago. The model showed mild phenotype with relatively modest penetrance compared to models generated on BALBc or NOD backgrounds. The generation of all these experimental models is crucial for development and testing new therapeutics as well as reading the response to treatments.

Indexed as

Gene Expression RegulationThymocytesAnimalsAntigensEpithelial CellsMiceMice, Inbred NODMice, KnockoutMutationThymus GlandAntigens

Identifiers

PMID36685668
PMCPMC9848810
OpenAlexW4315631824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.